BREAKING NEWS—Lilly's obesity drug Zepbound approved by FDA

Eli Lilly's tirzepatide, which is already approved for the treatment of diabetes under the trade name Mounjaro, late Wednesday was also authorized by the US Food and Drug Administration for the treatment of chronic weight management.

The GIP/GLP-1 receptor agonist will carry the trade name Zepbound for the obesity indication, and will compete with Danish firm Novo Nordisk’s already marketed obesity treatment Wegovy (semaglutide).

Check The Pharma Letter website for the full story on Thursday.